BRANFORD, Conn. / Jul 26, 2023 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced that it will be participating in the Canaccord Genuity 43rd Annual Growth Conference taking place at the InterContinental Boston Hotel on August 7-10, 2023.
Jeff Hawkins, Quantum-Si's Chief Executive Officer, will participate in the panel discussion “The Next Generation of Proteomics from the Research and Clinical Perspectives” on Thursday, August 10, at 10:00 AM ET.
Additionally, Jeff Hawkins will participate in a fireside chat on Thursday, August 10, at 12:30 PM ET.
A live and archived webcast of the event will be available in the “Investors” section of the Quantum-Si website under Events & Presentations.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing CompanyTM, is focused on revolutionizing the growing field of proteomics. The Company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at www.quantum-si.com.
| Last Trade: | US$1.14 |
| Daily Change: | -0.06 -5.00 |
| Daily Volume: | 3,526,235 |
| Market Cap: | US$157.780M |
February 18, 2025 February 13, 2025 January 28, 2025 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
